Company: PRME
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001628280-25-038619
Chunk: 35

Company: Prime Medicine, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 35
---
esAccumulatedDeficitTotalStockholders’Equity(in thousands, except share amounts)SharesAmountBalance as of December 31, 2024131,160,842 $2 $840,358 $1 $(687,212)$153,149 Stock-based compensation expense— — 5,681 — — 5,681 Change in unrealized loss on investments, net of tax— — — (16)— (16)Net loss— — — — (51,890)(51,890)Balance as of March 31, 2025131,160,842 $2 $846,039 $(15)$(739,102)$106,924 Exercise of pre-funded warrants3,199,984 — — — — — Issuance of common stock under the employee stock purchase plan133,612 — 197 — — 197 Stock-based compensation expense— — 6,325 — — 6,325 Change in unrealized loss on investments, net of tax— — — 5 — 5 Net loss— — — — (52,591)(52,591)Balance as of June 30, 2025134,494,438 $2 $852,561 $(10)$(791,693)$60,860 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

7

PRIME MEDICINE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

Common StockAdditionalPaid-inCapitalAccumulated OtherComprehensiveLossesAccumulatedDeficitTotalStockholders’Equity(in thousands, except share amounts)SharesAmountBalance as of December 31, 202397,377,121 $2 $624,414 $(15)$(491,330)$133,071 Issuance of common stock from public offering, net of issuance costs of $8.9 million22,560,001 — 132,055 — — 132,055 Issuance of pre-funded warrants, net of issuance costs of $1.2 million— — 18,800 — — 18,800 Issuance of common stock under the employee stock purchase plan74,488 —